Previous 10 | Next 10 |
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with this event. For further details see: BioCryst Pharmaceuticals (BCRX) Investor Presentation -Slideshow
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating rapid, sustained reduction of patient-reported HAE attacks and consistently low attack rates among patients 12 years and o...
After an ~11% decline following the company’s Q3 2022 results, BioCryst Pharmaceuticals ( NASDAQ: BCRX ) rose ~2% pre-market Wednesday as Evercore ISI upgraded the hereditary angioedema (HAE) drugmaker urging investors to buy on the dip. With its earnings on Tuesday...
Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q3 2022 Earnings Call Nov 01, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript ...
Updated to indicate the latest share price move. Despite exceeding Street forecasts with its Q3 2022 results, BioCryst Pharmaceuticals ( NASDAQ: BCRX ), the maker of hereditary angioedema (HAE) therapy Orladeyo fell ~11% on Wednesday. However, the biotech set its full ye...
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Conference Call November 01, 2022 08:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charli...
Despite exceeding Street forecasts with its Q3 2022 results, BioCryst Pharmaceuticals ( NASDAQ: BCRX ), the maker of hereditary angioedema (HAE) therapy Orladeyo fell ~15% in the morning hours Tuesday after reporting lower than expected sales for the treatment. Howev...
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: BioCryst Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation
BioCryst Pharmaceuticals press release ( NASDAQ: BCRX ): Q3 GAAP EPS of -$0.23 beats by $0.07 . Revenue of $75.8M (+84.9% Y/Y) beats by $1.02M . Cash, cash equivalents, restricted cash and investments totaled $462.6M at September 30, 2022, compared to $203.9M a...
—$66.0 million in ORLADEYO Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021— —Underlying patient trends remain strong with nine percent paid patient growth in Q3 2022— —Company expands complement pi...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...